The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Functional role of M2 and M3 muscarinic receptors in the urinary bladder of rats in vitro and in vivo
Open accessAbstract
Urinary bladder smooth muscle is enriched with muscarinic receptors, the majority of which are of the M 2 subtype whereas the remaining minority belong to the M 3 subtype. The objective of the present study was to assess the functional role of M 2 and M 3 receptors in the urinary bladder of rat in vitro and in vivo by use of key discriminatory antagonists. In the isolated bladder of rat, (+)‐cis‐dioxolane produced concentration‐dependent contractions (pEC 50=6.3) which were unaffected by tetrodotoxin (0.1 μ m). These contractions were antagonized by muscarinic antagonists with the following rank order of affinity (pA 2) estimates: atropine (9.1) > 4‐diphenyl acetoxy‐methyl piperidine methiodide (4‐DAMP) (8.9) > darifenacin (8.5) > para fluoro hexahydrosiladifenidol (p‐F‐HHSiD) (7.4) > pirenzepine (6.8) > methoctramine (5.9). These pA 2 estimates correlated most favourably (r=0.99, P<0.001) with the binding affinity (p Ki) estimates of these compounds at human recombinant muscarinic m 3 receptors expressed in Chinese hamster ovary cells, suggesting that the receptor mediating the direct contractile responses to (+)‐cis‐dioxolane equates with the pharmacologically defined M 3 receptor. As M 2 receptors in smooth muscle are negatively coupled to adenylyl cyclase, we sought to determine whether a functional role of M 2 receptors could be unmasked under conditions of elevated adenylyl cyclase activity (i.e., isoprenaline‐induced relaxation of KCl pre‐contracted tissues). Muscarinic M 3 receptors were preferentially alkylated by exposing tissues to 4‐DAMP mustard (40 n m, 1 h) in the presence of methoctramine (0.3 μ m) to protect M 2 receptors. Under these conditions, (+)‐cis‐dioxolane produced concentration‐dependent reversal (re‐contraction) of isoprenaline‐induced relaxation (pEC 50=5.8) but had marginal effects on pinacidil‐induced, adenosine 3′:5′‐cyclic monophosphate (cyclic AMP)‐independent, relaxation. The re‐contractions were antagonized by methoctramine and darifenacin, yielding pA 2 estimates of 6.8 and 7.6, respectively. These values are intermediate between those expected for these compounds at M 2 and M 3 receptors and were consistent with the involvement of both of these subtypes. In urethane‐anaesthetized rats, the cholinergic component (∼55%) of volume‐induced bladder contractions was inhibited by muscarinic antagonists with the following rank order of potency (ID 35%inh, nmol kg−1, i.v.): 4‐DAMP (8.1) > atropine (20.7) > methoctramine (119.9) > darifenacin (283.3) > pirenzepine (369.1) > p‐F‐HHSiD (1053.8). These potency estimates correlated most favourably (r=0.89, P=0.04) with the p Ki estimates of these compounds at human recombinant muscarinic m 2 receptors. This is consistent with a major contribution of M 2 receptors in the generation of volume‐induced bladder contractions, although the modest potency of darifenacin does not exclude a role of M 3 receptors. Pretreatment with propranolol (1 mg kg−1, i.v.) increased the ID 35%inh of methoctramine significantly from 95.9 to 404.5 nmol kg−1 but had no significant effects on the inhibitory responses to darifenacin. These data suggest an obligatory role of β‐adrenoceptors in M 2 receptor‐mediated bladder contractions in vivo. The findings of the present study suggest that both M 2 and M 3 receptors can cause contraction of the rat bladder in vitro and may also mediate reflex bladder contractions in vivo. It is proposed that muscarinic M 3 receptor activation primarily causes direct contraction of the detrusor whereas M 2 receptor activation can contract the bladder indirectly by reversing sympathetically (i.e. β‐adrenoceptor)‐mediated relaxation. This dual mechanism may allow the parasympathetic nervous system, which is activated during voiding, to cause more efficient and complete emptying of the bladder. British Journal of Pharmacology (1997) 120, 1409–1418; doi:10.1038/sj.bjp.0701048
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yung-Chi, C., & Prusoff, W. H. (1973) · Biochemical Pharmacology · doi:10.1016/0006-2952(73)90196-2 · Cited by 12,922
Muscarinic Receptors—Characterization, coupling and function
Caulfield, M. P. (1993) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(93)90027-b · Cited by 1,277
International Union of Pharmacology nomenclature of adrenoceptors.
Bylund, D. B., Eikenberg, D. C., Hieble, J. P., Langer, S. Z., Lefkowitz, R. J., Minneman, K. P., Molinoff, P. B., Ruffolo, R. R., & Trendelenburg, U. (1994) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06780-8 · Cited by 1,218
Furchgott, R. F. (1972) · Catecholamines · doi:10.1007/978-3-642-65249-3_9 · Cited by 806
Muscarinic receptor subtypes and smooth muscle function
Eglen, R., Hegde, S., & Watson, N. (1996) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06957-1 · Cited by 544
Self-citationThe classification of drugs and drug receptors in isolated tissues.
Kenakin, T. P. (1984) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06644-x · Cited by 480
PARKER, R. B., & WAUD, D. R. (1971) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)28846-2 · Cited by 443
Nervous control of the urogenital system
Maggi, C. A. (1993) · Harwood Academic Publishers eBooks · Cited by 371
Muscarinic acetylcholine receptor subtypes in smooth muscle
Eglen, R. M., Reddy, H., Watson, N., & Challiss, R. A. J. (1994) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(94)90047-7 · Cited by 247
Self-citationFunctional role for the M2 muscarinic receptor in smooth muscle of guinea pig ileum.
Thomas, E. A., Baker, S. A., & Ehlert, F. J. (1993) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)13113-1 · Cited by 104
Tobin, G., & Sjögren, C. (1995) · European Journal of Pharmacology · doi:10.1016/0014-2999(95)00221-6 · Cited by 85
Vaughan, C. W., & Satchell, P. M. (1995) · Progress in Neurobiology · doi:10.1016/0301-0082(95)80012-w · Cited by 82
Reddy, H., Watson, N., Ford, A. P. D. W., & Eglen, R. M. (1995) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1995.tb14904.x · Cited by 60
Self-citationMuscarinic Receptor Subtypes in Smooth Muscle
(2020) · CRC Press eBooks · doi:10.1201/9781003069027 · Cited by 51
Thomas, E. A., & Ehlert, F. J. (1996) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)02396-8 · Cited by 46
Leung, E., Michelson, S., Villarrubia, C., Perkins, L. A., & Eglen, R. M. (1992) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/1056-8719(92)90006-m · Cited by 27
Self-citationMuscarinic receptor subtypes in human and rabbit bladder
Ruggieri, M. R., Bode, D. C., Levin, R. M., et al. (1987) · Neurourology and Urodynamics · doi:10.1002/nau.1930060209 · Cited by 20
Coley, C., Woodward, R., Naylor, L. H., & Strange, P. G. (1996) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1996.tb17244.x · Cited by 3
Cited by
Urinary Bladder Contraction and Relaxation: Physiology and Pathophysiology
Andersson, K.-E., & Arner, A. (2004) · Physiological Reviews · doi:10.1152/physrev.00038.2003 · Cited by 949
Drugs, their targets and the nature and number of drug targets
Imming, P., Sinning, C., & Meyer, A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2132 · Cited by 839
Abrams, P., Andersson, K., Buccafusco, J. J., Chapple, C., de Groat, W. C., Fryer, A. D., Kay, G., Laties, A., Nathanson, N. M., Pasricha, P. J., et al. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706780 · Cited by 632
Andersson, K.-E., & Wein, A. J. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.4.4 · Cited by 484
Matsui, M., Motomura, D., Karasawa, H., Fujikawa, T., Jiang, J., Komiya, Y., Takahashi, S.-I., & Taketo, M. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.17.9579 · Cited by 450
Metadata
- Authors
- Hegde, S. S., Choppin, A., Bonhaus, D., Briaud, S., Loeb, M., Moy, T. M., Loury, D., & Eglen, R. M.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 1997-04
- Volume
- 120
- Issue
- 8
- Pages
- 1409-1418
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2022805127
- Cited by
- 300
- References
- 18
- FWCI
- 19.35
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.